Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dipeptidyl peptidase IV (DPP-IV) has been revealed as an adipokine with potential relevance in cardiovascular disease (CVD), while clinically used DPP-IV inhibitors have demonstrated beneficial cardiovascular effects in several experimental studies. Perivascular adipose tissue (PVAT) is a unique adipose tissue depot in close anatomical proximity and bidirectional functional interaction with the vascular wall, which is a source of DPP-IV and its biology may be influenced by DPP-IV inhibition. Recently, DPP-IV inhibition has been associated with decreased local inflammation and oxidative stress both in the vascular wall and the PVAT, potentially regulating atherogenesis progression in vivo. DPP-IV inhibition may thus be a promising target in cardiovascular disease. However, the exact pleiotropic mechanisms that underlie the cardiovascular effects of DPP-IV inhibition need to be clarified, while the in vivo benefit of DPP-IV inhibition in humans remains unclear.

Original publication

DOI

10.1016/j.vph.2017.07.001

Type

Journal article

Journal

Vascul Pharmacol

Publication Date

09/2017

Volume

96-98

Pages

1 - 4

Keywords

Atherosclerosis, DPP-IV inhibitors, Oxidative stress, Perivascular adipose tissue, Adipose Tissue, Animals, Anti-Inflammatory Agents, Antioxidants, Atherosclerosis, Blood Vessels, Cardiovascular Agents, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Humans, Oxidative Stress, Signal Transduction